MedTrace Logo

Clinical Study of OncoSorb® in Patients With Advanced Cancer Entities

NCT01013168 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2011-07-22

No results posted yet for this study

Summary

The purpose of this study is to collect further data for safety and feasibility for the use of the medical device OncoSorb® in clinical routine for the treatment of patients with solid metastatic cancer entities who have failed standard therapies. OncoSorb® device is intended to specifically adsorb three soluble receptors (sTNF-R1, sTNF-R2 and sIL-2R α), which are known to inhibit the natural immune response of cancer patients mediated via tumor necrosis factor α (TNF- α).

Conditions

  • Advanced Cancer Entities

Interventions

PROCEDURE

Apheresis using the OncoSorb column

device is intended to specifically adsorb three soluble receptors (sTNF-R1, sTNF-R2 and sIL-2R α)

Sponsors & Collaborators

  • Dr. M. Koehler GmbH

    collaborator UNKNOWN

  • ARTIMED Medical Consulting GmbH

    collaborator UNKNOWN

  • BioPheresis GmbH

    lead INDUSTRY

Principal Investigators

  • Juergen Krauss, MD · Nationales Centrum für Tumorerkrankungen (NCT)

  • Niels Emmerich, PhD · BioPheresis GmbH

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2010-04-30
Completion
2011-02-28

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01013168 on ClinicalTrials.gov